MTNR1A and neurodegenerative disease: Certain MT1 agonists, including Agomelatine, Ramelteon, and Tasimelteon that are used clinically for sleep disorders (Kato et al., 2005; Kuriyama et al., 2014; Liu et al., 2016), have the potential to inhibit neuroinflammation, further remitting neuron loss and alleviate motor symptoms in PD or other neurodegenerative diseases like AD.